Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C. Merchan JR, et al. Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3. Cancer Chemother Pharmacol. 2015. PMID: 25556030 Free PMC article. Clinical Trial.
A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology.
Warsame R, Cook J, Fruth B, Hubbard J, Croghan K, Price KAR, Jatoi A, Kumar S, Thompson C, Buckner J, Dispenzieri A, Sloan J, Dueck AC. Warsame R, et al. Among authors: fruth b. Contemp Clin Trials Commun. 2022 Jul 13;29:100964. doi: 10.1016/j.conctc.2022.100964. eCollection 2022 Oct. Contemp Clin Trials Commun. 2022. PMID: 35928285 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 37702582
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. Abuzakhm SM, et al. Among authors: fruth b. Endocr Relat Cancer. 2023 Sep 13;30(11):e220301. doi: 10.1530/ERC-22-0301. Print 2023 Nov 1. Endocr Relat Cancer. 2023. PMID: 37702588 Free PMC article. Clinical Trial.
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Chakrabarti S, et al. Among authors: fruth b. Oncologist. 2020 May;25(5):380-e763. doi: 10.1634/theoncologist.2019-0874. Epub 2019 Dec 11. Oncologist. 2020. PMID: 31826977 Free PMC article. Clinical Trial.
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Tella SH, et al. Among authors: fruth b. Oncologist. 2023 Oct 3;28(10):917-e966. doi: 10.1093/oncolo/oyad144. Oncologist. 2023. PMID: 37339254 Free PMC article. Clinical Trial.
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Zhu M, et al. Clin Cancer Res. 2022 Jul 15;28(14):3021-3031. doi: 10.1158/1078-0432.CCR-22-0413. Clin Cancer Res. 2022. PMID: 35552651 Free PMC article. Clinical Trial.
67 results